Article

Afinitor approved for rare pancreatic cancer

Author(s):

Late yesterday on May 5, the Food and Drug Administration approved Afinitor (everolimus) to treat patients with metastatic or inoperable advanced pancreatic neuroendocrine tumors (PNET), sometimes also called islet cell tumors. Patients with this rare tumor type have few treatment options, and there hasn't been a new treatment approved in about 30 years.The approval was expected and comes on the heels of a unanimous recommendation from the FDA's Oncologic Drugs Advisory Committee (ODAC) on April 12.The committee's decision was based on the phase 3 trial RADIANT-3, which randomly assigned 410 patients to either receive Afinitor or a placebo. Afinitor showed more than double the progression free survival, which was 11 months with the drug compared with 4.6 with placebo. Patients on placebo were given the opportunity to receive Afinitor after disease progression. Data on overall survival is not yet available. You can read more details about the study in the Feb. 10 issue of The New England Journal of Medicine.The most common side effects from Afinitor reported were mouth inflammation, rash, diarrhea, fatigue and infection (generally upper respiratory). Afinitor also is approved for treating patients with advanced kidney cancer who have been previously treated with Nexavar (sorafenib) or Sutent (sunitinib). Sutent incidentally was also recommended by the ODAC for treating pancreatic neuroendocrine tumors but has yet to receive FDA approval.

Related Videos
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Bald Doctor.
Related Content